- ticket title
- Deputy Minister of Interior Visits Narcotics Department
- GNA Council of Ministers Announces Resumption of Air Traffic at Amitiq Airport
- German Foreign Minister: Libya’s neighboring countries suffer from negative consequences of Libyan Crisis
- Libya – IDP and Returnee Key Findings Report 28 (Nov-Dec 2019)
- Activities of Secretary-General in Germany, 18-20 January
GENEVA, SWITZERLAND–(Marketwire – Sept. 19, 2012) – EasyMed Services Inc.® (CNSX:EZM)(OTCBB:EMYSF)(MUN:
According to the report, EquityNet initiated a BUY rating for EasyMed with a 12-month target price of $4.12 (USD).
The focus of the report is on two of EasyMed’s core services: Easy SmartCare, the Company’s two-way communication system for patients and provider organizations; and the International Medical Passport, an online personal health record and service finder that goes with travellers anywhere in the world they do.
According to the report, the smartphone application market for mobile healthcare will reach $1.3 billion (USD) in 2012 — up from $718 million in 2011. Despite this substantial growth, the “mHealth” market is still in its infant stage — especially when compared to the $6 trillion of the overall global healthcare market. Several factors, especially smartphone penetration and national healthcare cost reduction programs, will continue, however, to drive mHealth market growth.
“We feel that the Company is certainly in the right place at the right time. It is obvious that demand is and will remain very strong for mobile health ‘mHealth’ applications well into the foreseeable future, and the market itself is huge. Valuations for most health IT stocks have remained relatively strong despite recent market turbulence,” stated Mr. Randy Lewis, CFA, Founder and Senior Analyst with EquityNet who is covering the Company. “In addition, we feel the company’s International Medical Passport is a particularly strong product, lending itself to a subscription model, which typically has an exponential effect on revenue when a product or service catches on.”
Mr. Tejinder Sahota, CEO of EasyMed Services, comments, “In the broader perspective of the public markets it is essential to raise market awareness for EasyMed Services, Inc. This independent research report focuses in on the overall underlying trends in the telemedicine market but also puts a spotlight on the technological and commercial edge that the company has developed in penetrating this huge market. Our recent commercialisation efforts in the emerging markets, where we enjoy very strong relationships, were underlined in EquityNet’s research report and we feel that this again makes a strong case for greater value in the future for our company.”
About EasyMed’s International Medical Passport
The International Medical Passport makes medical records accessible worldwide by smartphone – an important service for all business travellers. Today’s global travellers need instant access to their health records in case of an emergency. The International Medical Passport puts the complete record on a smartphone together with instant access to pre-approved doctors, clinics and hospitals around the world. The Medical Passport works on all phone, PDA and web platforms and operates in over 80 countries with 300+ mobile carriers. Cloud-based, secure, compliant and accessible on iPhone, Android, Windows and Blackberry platforms, EasyMed’s International Medical Passport meets HIPAA requirements, supports HL-7 (the global authority on standards for interoperability of health information technology) and is IBM certified.
About EasyMed’s Easy SmartCare
Easy SmartCare allows clinics, hospitals and doctors’ practices to communicate with patients through text messages on their smartphones and other mobile devices. Easy SmartCare reduces missed appointments, improves preparation, sends medication reminders and improves overall outpatient management, and clinical trials have shown immediate and positive financial benefits.
About EasyMed Services Inc.
EasyMed Services Inc. (CNSX:EZM)(OTCBB:EMYSF)(MUN:
About EquityNet Research
EquityNet Research, an independent equity research firm, was formed to provide the public with independent, objective research on under-followed companies. It does this by preparing detailed reports that highlight the key aspects of each company and its industry. EquityNet does not have extraneous relationships with its followed-companies nor has any present or future pecuniary benefit other than that disclosed for each company on its website. EquityNet was compensated $20,000 (USD) by the subject company for the preparation of the EasyMed report. EquityNet is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any specific securities.
This news release may contain forward-looking statements, which relate to future events or future performance, such as the continuing roll-out of the Company’s primary product and the benefits of such products that may be realized by the Company’s targeted customers, and reflect management’s current expectations and assumptions about such future events or future performance. Forward looking statements may also include, without limitation, any statement relating to future conditions or circumstances. These forward‐looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company and its management. Investors are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances or to reflect changes in the beliefs or opinions of the Company’s management.
The CNSX has not reviewed this release and therefore does not accept responsibility for the adequacy or accuracy of this release.